Hanall Biopharma (009420.KS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · South Korea · ISIN KR7009420001
Hanall Biopharma financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 138.94 bn KRW | 155.18 bn KRW |
| Gross profit | 73.31 bn KRW | 80.86 bn KRW |
| Operating income | 230.47 m KRW | -915.81 m KRW |
| EBIT | -112.23 m KRW | -6.04 bn KRW |
| Net income | -1.80 bn KRW | -5.56 bn KRW |
| Diluted EPS – continuing operations | -35.59 KRW | -109.48 KRW |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson's disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves' disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.
More stocks
- Corporativo GBM S.A.B. de C.V (GBMO.MX)
- Glenveagh Properties PLC (GVR.IR)
- TOMPKINS FINANCIAL CORP (TMP)
- Dominos PIZZA Enterprises Ltd (DMP.AX)
- Hubei Zhongyi Science Technology Co. Ltd. (301150.SZ)
- SHANDONG HI-TECH SPRING MATERIAL T (301292.SZ)
- agilon health, inc. (AGL)
- Kunshan Huguang Auto Harness Co Ltd (605333.SS)
- SonoScape Medical Corp (300633.SZ)
- SPG Co. Ltd (058610.KQ)
- Supreme Electronics Co Ltd (8112.TW)
- Burke & Herbert Financial Services Corp. (BHRB)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.